Tissue Removal During Hysterectomy: The Effect of Vaginal Versus Abdominal Morcellation on Surgical Outcomes

June 1, 2023 updated by: George Washington University
In this study the investigators will perform a randomized trial to compare the surgical outcomes of vaginal versus abdominal morcellation of the uterus during hysterectomy. In minimally invasive gynecologic surgery small incisions are made in the abdomen and pelvis so that a hysterectomy can be performed by laparoscopy. The challenge is then to remove the uterus, which may be quite large, through these small incisions. One option is to morcellate the uterus and remove the tissue through either a small abdominal incision or an incision in the vagina. When an organ is morcellated it is cut into smaller pieces so that it can be removed, section by section, through a small incision. The investigators will compare these two methods of tissue removal to see whether one results in better surgical outcomes or increased intra-operative or post-operative complications. The primary outcome will be the time it takes to perform the surgery (operative time). Secondary surgical outcomes that will be studied include the amount of blood lost during surgery, post-operative complications, and readmission to the hospital.

Study Overview

Status

Withdrawn

Conditions

Detailed Description

Hysterectomy is the most commonly performed non-obstetric procedure in women in the United States, with approximately 400,000 hysterectomies performed each year. Minimally invasive techniques have all been shown to have advantages over laparotomy. These include decreased blood loss, faster recovery time, improved postoperative pain and decreased postoperative complications including wound infections, thromboembolism, iatrogenic injuries and incisional hernias. Due to all of these benefits, the volume of minimally invasive procedures has increased significantly over the last ten years making tissue extraction a widely debated topic.

Morcellation is a technique that allows large pieces of tissue to be removed through small incisions and was originally performed either with a scalpel or manual device until the first power/electric morcellators were introduced in 1993. Since then, power morcellation has made 50,000 to 150,000 minimally invasive hysterectomies possible annually. While the former has been an integral part in the treatment of women with large uteri and uterine fibroids, it has recently come under scrutiny due to multiple concerns including dissemination of undetected malignancy, development of iatrogenic myomas as well as increased number of reported complications and death. This has led the US Food and drug administration in April 2014 to issue a statement discouraging the use of laparoscopic power morcellation.

In the face of the growing bias against electronic mechanical morcellators, other approaches must be investigated and promulgated so that patients may still benefit from minimally invasive gynecologic surgeries. The two commonly used methods for tissue extraction are manual morcellation through mini-laparotomy and vaginal morcellation. In the former, a trocar site enlargement or a new up to 1 inch incision is created through which the specimen is brought to the abdominal surface and morcellated with scalpel.In the latter, tissues are removed in the same fashion but via a colpotomy. The investigators intent is to compare manual morcellation methods (vaginal vs abdominal mini-laparotomy) in order to help surgeons choose the best approach for their patient.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • District of Columbia
      • Washington, District of Columbia, United States, 20037
        • George Washington University Medical Faculty Associates

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 61 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Hysterectomy planned for a benign gynecologic reason
  • Patient is scheduled to have surgery with one of the minimally invasive gynecologic surgeons at George Washington University Hospital. (Dr. Moawad, Dr. Marfori, or Dr. Vargas)
  • Patient is planned for a robotic assisted total laparoscopic hysterectomy (RA-TLH) or a total laparoscopic hysterectomy (TLH)
  • Patient is capable of informed consent
  • Patient must be between 18 and 65 years of age
  • Uterus greater than 12 centimeters in height and 4 centimeters in width or 12 weeks in size

Exclusion Criteria:

  • Hysterectomy is indicated for malignancy
  • Procedure is anything other than RA-TLH or TLH
  • Surgeon is not one of hte minimally invasive surgeons at GWUH
  • Surgery is scheduled for a hospital other than GWUH
  • Patient does not meet the age requirements.
  • Patient is not capable of informed consent
  • Uterus is less than 12 cm in heightand 4 cm in width

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: abdominal morcellation
Women randomized to this group will undergo abdominal morcellation.
patients will be randomized to receive abdominal morcellation
Active Comparator: vaginal morcellation
Women randomized to this group will undergo vaginal morcellation.
patients will be randomized to receive vaginal morcellation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total operative time
Time Frame: Perioperative
Time (in minutes) from when first cut is made until last suture is made.
Perioperative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Loss
Time Frame: perioperative
as measured in cubic centimeters (cc)
perioperative
Intraoperative complications
Time Frame: perioperative
Intraoperative complications include: Organ injury (bladder, bowel, vaginal laceration), Estimated Blood Loss>1000cc, and conversion to laparotomy
perioperative
Post-operative complications
Time Frame: as recorded between end of operation and 4 weeks post operation
Post-operative complications include: Reoperation, Intensive Care Unit (ICU) admission, Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE), transfusion, Readmission, Bowel obstruction/ileus, Incision seroma/cellulitis/hematoma/separation/hernia, and cuff cellulitis/abcess/dehiscence/granulation tissue
as recorded between end of operation and 4 weeks post operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gaby Moawad, MD, George Washington University Medical Faculty Associates

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Estimated)

May 1, 2023

Study Completion (Estimated)

May 1, 2023

Study Registration Dates

First Submitted

February 8, 2016

First Submitted That Met QC Criteria

March 3, 2016

First Posted (Estimated)

March 9, 2016

Study Record Updates

Last Update Posted (Actual)

June 5, 2023

Last Update Submitted That Met QC Criteria

June 1, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fibroids

Clinical Trials on abdominal morcellation

Subscribe